Thwarted in her ambition to become a brewmaster, Kiran Mazumdar-Shaw channeled her frustrations into building a knockoff drug ...

The final barrier is trust, and we can’t build it without education and advocacy Even if we have the right policies and systems in place, biosimilar medicines can only deliver their full impact ...

Teva outlines its accelerated growth strategy focused on innovation, aiming for $5 billion in biopharma revenue by 2030, ...

In a bid to allay conflict-of-interest concerns, Korean manufacturing giant Samsung Biologics is decoupling from its ...

a lack of physician education has been one of the reasons biosimilar uptake has been slower in the US. Manufacturers can work with a commercialisation partner to build provider confidence through ...

BENGALURU/HYDERABAD May 8 (Reuters) - Indian biopharma firm Biocon's (BION.NS), opens new tab profit more than doubled in the fourth quarter, led by strong demand for its generics and biosimilar ...

Teva outlines acceleration path into a leading biopharma companyInnovative medicines franchise on track to exceed $5 billion ...

Blake Powers: I’m excited about Blue Fin’s panel on biosimilars. Cell and gene therapy is also a ... moving beyond email and Zoom to build stronger, face-to-face relationships with industry partners.

Moving on to AVT04, our biosimilar to Stelara, we continue to build on the strong launch of this biosimilar under the UZPRUVO brand with STADA in Europe. In Europe, we were the first to market ...

Independent pharmacists worry that tariffs could drive companies out of business while raising prices and creating drug ...

“Our biosimilars continue to build impressive shares in global markets,” said Shreehas Tambe, CEO of Biocon Biologics. “We are well positioned to launch five new products in the next 12–18 ...

The IP team at Morais Leitão discusses high-stakes litigation, strategic partnerships with clients, and bolstering ...